Why nutraceuticals do not prevent or treat Alzheimer's disease.
A great deal of research has pointed to deleterious roles of metal ions in the development of Alzheimer's disease. These include: i) the precipitation and aggregation of amyloid beta (Abeta) peptides to form senile plaques and neurofibrillary tangles, and/or ii) the augmentation of oxidative stress by metal ion mediated production and activation of hydrogen peroxide. The growing trend in nutraceutical intake is in part a result of the belief that they postpone the development of dementias such as Alzheimer's disease. However, pathogenic events centred on metal ions are expected to be aggravated by frequent nutraceutical intake. Novel therapeutic approaches centred on chelators with specificity for copper and iron ions should be fully explored.
Fisher
Anna E O
AE
School of Pharmacy and Biomolecular Sciences, University of Brighton, Cockcroft Building, Moulsecoomb, Brighton, UK. af19@bton.ac.uk
Naughton
Declan P
DP
D000544:Alzheimer Disease / Q000178:diet therapy* / Q000209:etiology / Q000517:prevention & control*; D016229:Amyloid beta-Peptides / Q000378:metabolism; D000975:Antioxidants / Q000008:administration & dosage; D002614:Chelating Agents / Q000627:therapeutic use; D003300:Copper; D006801:Humans; D007501:Iron; D008670:Metals; D016874:Neurofibrillary Tangles / Q000737:chemistry; D009747:Nutritional Physiological Phenomena; D018384:Oxidative Stress; D058225:Plaque, Amyloid / Q000737:chemistry; D014815:Vitamins / Q000008:administration & dosage
D016229:Amyloid beta-Peptides; D000975:Antioxidants; D002614:Chelating Agents; D008670:Metals; D014815:Vitamins; D003300:Copper; D007501:Iron